Company Profile
10x Genomics Stock Price, News & Analysis
- Ticker:
- TXG
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
45.60 USD (-3.92%)
Close
Last updated: August 6, 2026
3.9B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, TXG closed down 3.92% at $45.60. No new same-company headline was identified in the current news window.
Company overview
Business overview
10x Genomics is a life sciences tools company focused on single-cell and spatial biology technologies. Its products help researchers study biology at high resolution and support discovery across genomics and translational research.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, 10x Genomics has a global footprint in research tools. It sits in the biotech infrastructure layer rather than therapeutics.
Business Model Characteristics
The company generates revenue from instruments, consumables, and workflow technologies used in genomics research. Investors watch academic and biopharma spending, product adoption, and the pace of platform utilization.
Position Within the Biotechnology Landscape
10x Genomics is one of the most important tools names in modern biology because it powers discovery across the life sciences. It is not a drug company, but it is highly relevant to biotech research spending.
Future catalysts
10x Genomics’ catalysts are Xenium adoption, Chromium demand, and any evidence that consumables recovery is finally broadening. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
- 01
- 02
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
Source: 10x Genomics
- 03
10x Genomics Reports Second Quarter 2021 Financial Results
Source: 10x Genomics
- 04
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
Source: 10x Genomics
- 05
10x Genomics Introduces New Chromium X Series for Single Cell Analysis
Source: 10x Genomics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of 10x Genomics (TXG)?
10x Genomics (TXG) most recently closed at 45.60 USD, a -3.92% move versus the previous session.
What is the market cap of 10x Genomics (TXG)?
10x Genomics currently has a market capitalization of 3.9B USD on BioPharmSignal.
What does 10x Genomics do?
10x Genomics is a life sciences tools company focused on single-cell and spatial biology technologies. Its products help researchers study biology at high resolution and support discovery across genomics and translational research.
On which exchange is TXG stock listed?
10x Genomics (TXG) is associated with NASDAQ, United States, Biopharma.
What is Genomics?
10x Genomics’ catalysts are Xenium adoption, Chromium demand, and any evidence that consumables recovery is finally broadening.
Which conditions is 10x Genomics targeting with Genomics?
10x Genomics’ catalysts are Xenium adoption, Chromium demand, and any evidence that consumables recovery is finally broadening.
How does 10x Genomics describe recent progress with Genomics?
10x Genomics’ catalysts are Xenium adoption, Chromium demand, and any evidence that consumables recovery is finally broadening.
What is Xenium?
10x Genomics’ catalysts are Xenium adoption, Chromium demand, and any evidence that consumables recovery is finally broadening.